Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Pharmacogenomics|December 4, 2024
Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?Aaron K Wong, Sara Vogrin, Pal Klepstad, et al.
Journal of Palliative Medicine|September 10, 2024
Influence of <i>COMT</i> (rs4680) and <i>OPRM1</i> (rs1799971) on Cancer Pain, Opioid Dose, and Adverse EffectsAaron K Wong, Pal Klepstad, Andrew A Somogyi, et al.
Pharmacogenomics|December 21, 2023
Effect of gene variants on opioid dose, pain and adverse effect outcomes in advanced cancer: an explorative studyAaron K Wong, Pal Klepstad, Andrew A Somogyi, et al.
Journal of Palliative Medicine|November 13, 2023
Opioid Switch Dosing in Chronic Cancer Pain: A Prospective Longitudinal StudyAaron K Wong, Pal Klepstad, Justin P Rubio, et al.
BMJ Supportive & Palliative Care|July 19, 2018
Sleep quality with WHO Step III opioid use for cancer painGunnhild Jakobsen, Morten Engstrøm, Peter Fayers, et al.
Cancers|July 29, 2023
Effectiveness of Opioid Switching in Advanced Cancer Pain: A Prospective Observational Cohort StudyAaron K Wong, Andrew A Somogyi, Justin Rubio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2013
Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic systemBarry J Laird, Stein Kaasa, Donald C McMillan, et al.
Journal of Palliative Medicine|December 9, 2022
Establishing a Longitudinal Opioid Pharmacogenomic Registry for Cancer Patients: Feasibility and AcceptabilityJennifer Philip, Aaron Wong, Leeanne Pasanen, et al.
Palliative Medicine Reports|March 6, 2023
Benefits of Study Participation for Patients with Advanced Cancer Receiving Radiotherapy: A Prospective Observational StudyAsta Bye, Ellen Bjerkeset, Hanne Stensheim, et al.
Cancer Medicine|October 11, 2024
Development of a predictive model for patients with bone metastases referred to palliative radiotherapy: Secondary analysis of a multicenter study (the PRAIS trial)Romina Rossi, Federica Medici, Ragnhild Habberstad, et al.
Pageof 2